Sens. Back PTAB Denial Rules, Drug Pricing Activists Balk

Law360 (December 4, 2020, 10:59 PM EST) -- The depth of the rift over whether the U.S. Patent and Trademark Office should be denying patent challenges for reasons other than merit came fully to light, as 800 comments over codifying the practice poured in by the Thursday deadline.

Senate Judiciary Committee members and small businesses and inventors were pitted against finance organizations, generic-drug advocates and tech companies over whether the USPTO should create rules regarding its abilities to deny America Invents Act review petitions based on discretionary factors. Namely, that discretion would be used to deny serial petitions and petitions in cases where parallel district court litigation is at...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!